DAWN Revenue

In the year 2025, Day One Biopharmaceuticals had annual revenue of $158.18M with 20.60% growth. Day One Biopharmaceuticals had revenue of $53.72M in the quarter ending December 31, 2025, with 83.92% growth.

Revenue (ttm)

$158.18M

Revenue Growth

+20.60%

P/S Ratio

13.99

Revenue / Employee

$888,663

Employees

178

Market Cap

2.21B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	158.18M	27.02M	20.60%
Dec 31, 2024	131.16M	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Sarepta Therapeutics	2.20B
Apellis Pharmaceuticals	1.00B
Adaptive Biotechnologies	276.98M
Syndax Pharmaceuticals	172.35M
Immunome	6.94M
Celldex Therapeutics	1.55M

Revenue Rankings

DAWN News

18 days ago - Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - PRNewsWire
20 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - Newsfile Corp
20 days ago - Is there any upside left in DAWN stock as it soars 65%? - Invezz
21 days ago - Day One Shares Surge After $2.5B Servier Deal - Benzinga
21 days ago - Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion - Reuters
21 days ago - Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - GlobeNewsWire
21 days ago - Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth - Seeking Alpha
27 days ago - Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead - Seeking Alpha

More News